Skip to content
Screener

Glaukos GKOS Operating Income

Operating Income at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$7.14B+7.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.29B+19.8%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
-$3.89M+66.7%
AbbVie logo
AbbVieABBV
$6.43B+31.4%
Schering-Plough logo
Schering-PloughSGP
-$15.41M-108%
Bausch + Lomb logo
Bausch + LombBLCO
$83M+855%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.08B+98.7%
Enterprise value$10.07B+98.2%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Research and development51,30136,53895,44668,891
Acquired in-process research and development1,500-1,500-
Total operating expenses168,861119,913305,949222,939
Loss from operations(17,267)(22,689)(37,123)(43,367)
Non-operating income (expense):
Interest income2,2792,5744,7105,650
Interest expense(1,459)(1,151)(2,584)(2,314)
Other (expense) income, net(1,274)1,857(2,023)2,802

Item 1. Financial Statements

FAQ

What is Glaukos's operating income?
Glaukos (GKOS) reported operating income of -$17.27M in Q2 2026.
How has Glaukos's operating income changed year-over-year?
Glaukos's operating income increased by 23.9% year-over-year, from -$22.69M to -$17.27M.
What is the long-term trend for Glaukos's operating income?
Over 4 years (2021 to 2025), Glaukos's operating income has grown at a 57.0% compound annual growth rate (CAGR), from -$32.87M to -$199.6M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Glaukos's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude